Sanofi-Aventis (SNY) Says Multaq Study Shows 24% Cut in Cardio Hospitalization/Death -Bloomberg
More News related to SNY
- Video: Sanofi Pasteur Announces Final Results of U.S. Clinical Trials of Influenza A (H1N1) Vaccine in Adults and Children
- Morning Movers 11/11: NCST, SMI, MSN, CHLN, NLST, REGN Higher; TGIC, STS, CLWR, STV, MHR, MBLX Lower
- Sanofi-aventis (SNY) and Regeneron Pharmaceuticals (REGN) to Expand Global Collaboration
- Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
- Teva Pharmaceutical (TEVA) Announces Commercial Launch of Generic Allegra-D
More News related to Corporate News
- S&P Announces Changes to US Index: CMN for NTG, CVGW for STSA
- Kinross (KGC) Enters Agreement for $125M Letter of Credit Facility
- Endo Pharma (ENDP) Announces Settlement with LecTec Over Outstanding Patent Litigation
- Trubion Pharma (TRBN) Announces Two Presentations of TRU-016 Product at 2009 ASH Meeting
- S&P Revises Outlook on Sirius XM (SIRI) from Stable to Positive
Bloomberg is reporting that Sanofi-Aventis (NYSE: SNY) said Multaq results show statistical significance: Multaq reduced cardio hospitalization/death by 24%.
Related Categories
Corporate NewsStocks Mentioned
+0.11Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
